HK1220358A1 - 減毒活甲病毒製劑的組合物和方法 - Google Patents

減毒活甲病毒製劑的組合物和方法

Info

Publication number
HK1220358A1
HK1220358A1 HK16108388.5A HK16108388A HK1220358A1 HK 1220358 A1 HK1220358 A1 HK 1220358A1 HK 16108388 A HK16108388 A HK 16108388A HK 1220358 A1 HK1220358 A1 HK 1220358A1
Authority
HK
Hong Kong
Prior art keywords
live
compositions
methods
attenuated alphavirus
formulations
Prior art date
Application number
HK16108388.5A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jill A Livengood
Laszlo Varga
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1220358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of HK1220358A1 publication Critical patent/HK1220358A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16108388.5A 2013-03-14 2016-07-15 減毒活甲病毒製劑的組合物和方法 HK1220358A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784122P 2013-03-14 2013-03-14
PCT/US2014/026570 WO2014151855A1 (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations

Publications (1)

Publication Number Publication Date
HK1220358A1 true HK1220358A1 (zh) 2017-05-05

Family

ID=50489420

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108388.5A HK1220358A1 (zh) 2013-03-14 2016-07-15 減毒活甲病毒製劑的組合物和方法

Country Status (20)

Country Link
US (2) US10137186B2 (zh)
EP (2) EP3603667A1 (zh)
JP (3) JP6426695B2 (zh)
KR (1) KR20160003662A (zh)
CN (2) CN105377293B (zh)
AP (1) AP2015008733A0 (zh)
AU (2) AU2014236804B2 (zh)
BR (1) BR112015023205A2 (zh)
CA (1) CA2903711A1 (zh)
CR (1) CR20150553A (zh)
DO (1) DOP2015000226A (zh)
EC (1) ECSP20007842A (zh)
HK (1) HK1220358A1 (zh)
MX (2) MX361342B (zh)
MY (1) MY178476A (zh)
NZ (1) NZ631012A (zh)
PH (1) PH12015502115A1 (zh)
SG (3) SG10201801459SA (zh)
TW (2) TWI649087B (zh)
WO (1) WO2014151855A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361342B (es) 2013-03-14 2018-12-04 Takeda Vaccines Inc Composiciones y metodos para formulaciones de alfavirus vivos atenuados.
US10538785B2 (en) 2013-12-23 2020-01-21 Renaud Vaillant Lyophilized lentiviral vector particles, compositions and methods
KR20180135912A (ko) * 2016-03-31 2018-12-21 다케다 백신즈 인코포레이티드 개선된 제형을 이용한 알파바이러스의 안정화 조성물 및 방법
NL2022538B1 (en) * 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
US20230183657A1 (en) * 2021-01-19 2023-06-15 Nitta Gelatin Inc. Virus stabilizer, gelatin hydrolysate for virus stabilizer, and viruscontaining composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
RU2035508C1 (ru) * 1991-08-16 1995-05-20 Институт органической химии СО РАН Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
AU4594996A (en) * 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6465634B1 (en) * 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
EP1100944A1 (en) * 1998-07-30 2001-05-23 The Johns Hopkins University School Of Medicine Targeted alphavirus and alphaviral vectors
US6869907B2 (en) * 2000-05-02 2005-03-22 Pentax Corporation Color-image-forming medium
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
JP4550421B2 (ja) * 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
CA2482448C (en) 2002-04-11 2014-07-08 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
WO2005058356A2 (en) 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
US8865184B2 (en) * 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
EP2099485B1 (en) * 2006-11-03 2018-03-21 AlphaVax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
CA2668834C (en) 2006-11-07 2016-10-11 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
CN104083757A (zh) 2007-04-06 2014-10-08 武田疫苗公司 用于活的减毒病毒的方法和组合物
CN101835488B (zh) * 2007-09-04 2018-10-26 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) 轮状病毒的热灭活
SI2198007T1 (en) 2007-09-14 2018-04-30 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile A and B toxoids
EP3085787B1 (en) 2008-01-24 2020-10-28 The Board of Regents of the University of Texas System Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
BRPI0923341B8 (pt) * 2008-12-09 2021-05-25 Coley Pharm Group Inc oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso
JP6073031B2 (ja) * 2009-12-28 2017-02-01 タケダ ヴァクシーンズ， インコーポレイテッド インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法
PL2575873T3 (pl) * 2010-06-01 2016-06-30 Novartis Ag Zatężanie i liofilizacja antygenów szczepionkowych grypy
MX361342B (es) * 2013-03-14 2018-12-04 Takeda Vaccines Inc Composiciones y metodos para formulaciones de alfavirus vivos atenuados.

Also Published As

Publication number Publication date
JP2019031543A (ja) 2019-02-28
PH12015502115B1 (en) 2016-01-25
JP6426695B2 (ja) 2018-11-21
MY178476A (en) 2020-10-14
DOP2015000226A (es) 2016-02-29
US10137186B2 (en) 2018-11-27
AU2014236804A1 (en) 2015-10-01
MX361342B (es) 2018-12-04
US20190134182A1 (en) 2019-05-09
EP3603667A1 (en) 2020-02-05
AU2014236804B2 (en) 2018-12-13
SG11201507462QA (en) 2015-10-29
KR20160003662A (ko) 2016-01-11
SG10201909051QA (en) 2019-11-28
NZ631012A (en) 2017-08-25
EP2968515A1 (en) 2016-01-20
MX2015012894A (es) 2016-04-04
MX2018014977A (es) 2022-06-27
CA2903711A1 (en) 2014-09-25
JP2020193231A (ja) 2020-12-03
US20140271715A1 (en) 2014-09-18
US10806781B2 (en) 2020-10-20
WO2014151855A1 (en) 2014-09-25
CN105377293A (zh) 2016-03-02
JP6761015B2 (ja) 2020-09-23
CR20150553A (es) 2015-12-01
TW201900192A (zh) 2019-01-01
JP2016513658A (ja) 2016-05-16
BR112015023205A2 (pt) 2017-07-18
ECSP20007842A (es) 2020-09-30
TW201513875A (zh) 2015-04-16
AP2015008733A0 (en) 2015-09-30
PH12015502115A1 (en) 2016-01-25
AU2018236897B2 (en) 2020-09-10
EP2968515B1 (en) 2019-05-08
SG10201801459SA (en) 2018-03-28
CN111729077A (zh) 2020-10-02
TWI649087B (zh) 2019-02-01
AU2018236897A1 (en) 2018-10-18
CN105377293B (zh) 2020-07-17

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
HK1218837A1 (zh) 組合物和方法
HK1218560A1 (zh) 組成與方法
GB2520795B (en) Compositions and methods
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
ZA201505390B (en) Compositions and methods for treating pests
EP3065716C0 (en) FORMULATIONS
GB201308072D0 (en) Compositions and methods
IL241355B (en) Pyrazole-amide compounds, preparations containing them and their uses
GB201319792D0 (en) Formulations
HK1213800A1 (zh) 類毒素、組合物及相關方法
IL266767A (en) Compounds, compositions and methods for making dihydroxyphenyl neurotransmitter
EP2981529A4 (en) ORIDONIN ANALOGUES, COMPOSITIONS AND RELATED METHODS
IL242795B (en) Preparations, methods and devices for dialysis
EP2953455A4 (en) ANTIMICROBIAL COMPOSITIONS, WIPES AND METHODS
GB201305813D0 (en) Compositions and methods
IL243778A0 (en) Combined immune complexes
HK1220358A1 (zh) 減毒活甲病毒製劑的組合物和方法
HK1214951A1 (zh) 眼用製劑
PT3066199T (pt) Snorna, composições e utilizações
HK1213917A1 (zh) 類霉素、組合物及相關方法
HK1212916A1 (zh) 包含炮製提取物的組合物
EP3102557A4 (en) Improved compositions and methods comprising resveratrol
GB201313990D0 (en) Combination immunogenic compositions
GB201322617D0 (en) Methods and compositions